Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMBR | P28336 | 11/20 | 0.56 |
| ▸ | TACR1 | P25103 | 1/20 | 0.53 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.52 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.52 |
| ▸ | TACR3 | P29371 | 1/20 | 0.51 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.51 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4614285 | 0.90 | NMBR (0.52) | NMBRTACR1SIRT2SIRT1SIRT3 | |
| SCHEMBL6013894 | 0.89 | NMBR (0.61) | NMBRTACR1TACR3 | |
| SCHEMBL3795866 | 0.81 | NMBR (0.68) | NMBRSIRT5 | |
| SCHEMBL26418441 | 0.81 | NMBR (0.45) | NMBRTACR1 | |
| SCHEMBL26418455 | 0.81 | NMBR (0.45) | NMBRTACR1 | |
| SCHEMBL4888188 | 0.80 | KMT2A (0.42) | PIN1SIRT5 | |
| SCHEMBL9088692 | 0.80 | NMBR (0.72) | NMBRTACR1TACR3 | |
| SCHEMBL4930789 | 0.80 | NMBR (0.58) | NMBRTACR1TACR3 | |
| SCHEMBL4930779 | 0.80 | NMBR (0.58) | NMBRTACR1TACR3 | |
| SCHEMBL16915248 | 0.80 | NMBR (0.58) | NMBRTACR1TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | NMBR 2134/4885TACR1 2490/4885SIRT2 1616/4885 |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | POLQ, POLI, POLH | NMBR 3131/4885TACR1 4633/4885SIRT2 3095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.